For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Stock-based compensation | - | 643 | ||
| Salaries and personnel costs | - | 2,900 | ||
| Research and development | 5,055 | 12,537 | ||
| Other income | - | -374 | ||
| General and administrative | 3,964 | - | ||
| Total operating expenses | 9,019 | 17,878 | ||
| Loss from operations | -9,019 | - | ||
| Interest income, net | -134 | - | ||
| Foreign exchange gain (loss) | 54 | - | ||
| Insurance | - | 286 | ||
| Total other income, net | 188 | - | ||
| Net loss | -8,831 | -17,504 | ||
| Basic EPS | -0.78 | -1.72 | ||
| Diluted EPS | -0.78 | -1.72 | ||
| Basic Average Shares | 11,290,000 | 10,174,000 | ||
| Diluted Average Shares | 11,290,000 | 10,174,000 | ||
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)